Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of LAVA Therapeutics NV (NASDAQ: LVTX) closed at $1.48 in the last session, down -2.63% from day before closing price of $1.52. In other words, the price has decreased by -$2.63 from its previous closing price. On the day, 1.9 million shares were traded. LVTX stock price reached its highest trading level at $1.52 during the session, while it also had its lowest trading level at $1.44.
Ratios:
We take a closer look at LVTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.78 and its Current Ratio is at 10.78. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Leerink Partners on December 12, 2024, Downgraded its rating to Market Perform and sets its target price to $2 from $11 previously.
On October 25, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.H.C. Wainwright initiated its Buy rating on October 25, 2022, with a $9 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 14 ’25 when Cooperatieve Gilde Healthcare sold 227,341 shares for $1.51 per share. The transaction valued at 343,285 led to the insider holds 5,019,151 shares of the business.
Cooperatieve Gilde Healthcare sold 47,686 shares of LVTX for $73,436 on Oct 13 ’25. The 10% Owner now owns 5,246,492 shares after completing the transaction at $1.54 per share. On Oct 10 ’25, another insider, Cooperatieve Gilde Healthcare, who serves as the 10% Owner of the company, sold 49,869 shares for $1.55 each. As a result, the insider received 77,297 and left with 5,294,178 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LVTX now has a Market Capitalization of 38931840 and an Enterprise Value of -17237164. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.80 while its Price-to-Book (P/B) ratio in mrq is 1.95. Its current Enterprise Value per Revenue stands at -3.454 whereas that against EBITDA is 0.67.
Stock Price History:
The Beta on a monthly basis for LVTX is 0.49, which has changed by -0.14003485 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, LVTX has reached a high of $2.09, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -4.29%, while the 200-Day Moving Average is calculated to be 12.80%.
Shares Statistics:
According to the various share statistics, LVTX traded on average about 249.01K shares per day over the past 3-months and 419620 shares per day over the past 10 days. A total of 26.31M shares are outstanding, with a floating share count of 17.83M. Insiders hold about 32.23% of the company’s shares, while institutions hold 28.42% stake in the company. Shares short for LVTX as of 1759190400 were 116555 with a Short Ratio of 0.47, compared to 1756425600 on 88902. Therefore, it implies a Short% of Shares Outstanding of 116555 and a Short% of Float of 0.73.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of LAVA Therapeutics NV (LVTX) in the stock market.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.19 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.73 and -$0.73 for the fiscal current year, implying an average EPS of -$0.73. EPS for the following year is -$0.46, with 1.0 analysts recommending between -$0.46 and -$0.46.
